Fig. 1

Total pain burden (monthly severity-weighted duration in hours) for patients with episodic migraine and chronic migraine. Greater decreases in total pain burden (severity-weighted hours) were observed with galcanezumab treatment Months 1 to 6 overall for patients with episodic migraine and Months 1 to 3 overall for patients with chronic migraine